Latest News

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Assembly...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Merchants Bancorp recently announced dividends on its common stock and multiple preferred stock series, while Michael F. Petrie, Chairman and CEO, sold 2,177 Series C Depositary Shares after the Q3 2025 earnings report showed mixed results, including improved asset quality. Petrie's insider sales and ongoing substantial ownership highlight executive confidence and raise questions about leadership sentiment amid ongoing strategic initiatives. We'll explore how recent insider sales by the CEO...

Harrow, Inc. recently presented at major industry events and secured a key win as its dry eye therapy Vevye replaced Xiidra on the CVS Tier 1 formulary. This change gives Vevye first-line access at the largest pharmacy benefit manager in the US, which could significantly broaden adoption of Harrow’s flagship product. We’ll explore how Vevye’s elevated CVS formulary status may influence Harrow’s growth profile and long-term investment outlook. Rare earth metals are an input to most high-tech...

On November 20, 2025, Neurocrine Biosciences announced the publication of a comprehensive peer-reviewed narrative review consolidating over a decade of clinical research on the FDA-approved VMAT2 inhibitors INGREZZA and deutetrabenazine for tardive dyskinesia. The review highlights key differences in pharmacologic, dosing, and clinical profiles between the two treatments, providing practitioners with updated evidence derived from double-blind, placebo-controlled trials and long-term...

Jiayin Group Inc. recently reported its third quarter and nine-month 2025 financial results, with revenue reaching CNY 1.47 billion and CNY 5.13 billion, and net income of CNY 376.49 million and CNY 1.44 billion, respectively, both rising compared to the prior year. The company’s basic earnings per share from continuing operations also showed a clear increase for both the quarter and the year-to-date period. We'll take a look at how Jiayin Group's higher net income growth this quarter...

Wondering if Cintas is trading at a value that makes sense for your portfolio? You’re not alone, as the company’s share price has attracted attention from investors questioning whether the current price is justified. After a steady start to the year, Cintas has seen its stock rise 1.0% in the past week and 1.2% over the last month. It is still down 16.0% over the past year despite impressive multi-year gains. The recent price movement has been influenced by ongoing conversations around the...

As global markets navigate a complex landscape of economic indicators and policy shifts, small-cap stocks have recently captured investor attention, particularly as the Russell 2000 Index outperformed its large-cap counterparts with a notable 5.52% advance. Amid dovish Federal Reserve signals and mixed economic data, identifying promising small-cap opportunities involves assessing factors such as growth potential, market positioning, and financial resilience in the face of evolving consumer...

As global markets navigate a complex landscape of dovish Federal Reserve signals, subdued inflation in Europe, and resilient economic indicators in Japan, investors are keenly assessing opportunities that may arise from these shifting dynamics. In this environment, identifying stocks that are potentially undervalued can be crucial for those looking to capitalize on discrepancies between market prices and intrinsic values.

As global markets navigate a landscape marked by dovish Federal Reserve signals and mixed economic data, investors are keenly observing the potential for growth within various sectors. Amid these conditions, companies with strong insider ownership and robust revenue growth stand out as compelling opportunities, offering insights into their commitment to long-term success.

The Sequoia Logística e Transportes S.A. ( BVMF:SEQL3 ) share price has fared very poorly over the last month, falling...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Trupanion (TRUP) drew attention this week after reporting record subscription adjusted operating income and improved margins, supported by strong net pet additions and higher customer retention. The company also secured a sizable new credit facility and formed new brand partnerships. See our latest analysis for Trupanion. Trupanion’s recent string of positive operating updates has played out against a backdrop of notable volatility. Even with record-high adjusted operating income and new...

In the past week, Monster Beverage reported record quarterly figures, posting net sales, gross profit, operating income, and net income all at new highs, with revenue rising 16.8% year-on-year and international sales making up 43% of total net sales for the first time. This quarter's results mark the company's largest proportion of non-U.S. sales to date, signaling a significant shift toward greater global diversification. We'll explore how Monster Beverage's record international sales...

Wingstop recently marked the opening of its 3,000th restaurant globally, expanding its footprint by 50% in just two years and entering six new markets including Australia, Bahrain, Kuwait, Puerto Rico, Saudi Arabia, and The Netherlands as part of its goal to become a top 10 global restaurant brand. This milestone highlights the company's rapid pace of international expansion and its ambition to scale beyond 10,000 locations worldwide in the coming years. We'll explore how Wingstop's swift...

In the third quarter of 2025, Alkermes reported earnings from continuing operations of US$0.49 per share, surpassing expectations as its proprietary products portfolio saw sales rise 16% year over year, driven by demand for Vivitrol, Aristada, and Lybalvi. The company raised its full-year 2025 revenue guidance to a range of US$1.43 billion to US$1.49 billion, highlighting confidence in continued product demand and business momentum. We'll examine how Alkermes' stronger earnings and upgraded...

On November 18, 2025, First Mining Gold Corp. announced positive results from an updated Pre-Feasibility Study for its 100%-owned Springpole Gold Project in Ontario, Canada, highlighting ongoing work to advance project engineering and regulatory processes. A key insight from the announcement is the identification of opportunities to upgrade mineral resources and enhance project economics as First Mining continues consultations with local and Indigenous communities. Given these developments...

CK Hutchison Holdings has been in discussions with financial advisers regarding a potential listing of its health and beauty retailer AS Watson Group, with reports suggesting the move could raise US$2.6 billion or more in Hong Kong and possibly involve a dual listing in the UK. An interesting insight is that AS Watson operates over 17,000 stores in 31 markets, making this potential IPO one of the most significant retail listings out of Asia in recent years. We'll examine how the possible AS...

MGE Energy (MGEE) shares slipped slightly over the past week, continuing a downward trend that has stretched across several months. Even with recent earnings growth, investors seem unimpressed as the stock has lost 14% year-to-date. See our latest analysis for MGE Energy. This latest drop brings MGE Energy’s share price return for the year to a challenging -13.8%, reflecting fading investor momentum despite steady earnings growth and broader sector shifts. Looking at a longer timeframe, the...

The Middle East stock markets have been experiencing mixed performances, influenced by optimism surrounding potential U.S. Federal Reserve rate cuts and fluctuating oil prices. In this dynamic environment, identifying promising stocks involves looking for companies with strong fundamentals and growth potential that can navigate the current economic landscape effectively.

Key Insights Duality Biotherapeutics' estimated fair value is HK$664 based on 2 Stage Free Cash Flow to Equity Duality...

When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 17x, you may consider...